高级检索
当前位置: 首页 > 详情页

Radiomics predicts clinical outcome in primary gastroesophageal junction adenocarcinoma treated by chemo/radiotherapy and surgery(Open Access)

文献详情

资源类型:
WOS体系:

收录情况: ◇ ESCI

机构: [a]Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Texas, USA [b]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China [c]Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Texas, USA [d]Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Texas, USA [e]Department of Radiation Oncology, University of Nebraska Medical Center, Nebraska, USA [f]Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Texas, USA [g]Department of Diagnostic Radiology the University of Texas MD Anderson Cancer Center, Texas, USA [h]Department of Pathology, The University of Texas MD Anderson Cancer Center, Texas, USA [i]Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Texas, USA
出处:

关键词: Gastroesophageal junction adenocarcinoma Pathologic complete response Prognostic model Radiology Radiomics Survival Texture analysis

摘要:
Purpose: Radiomics has shown great promise to use quantifiable imaging characteristics to predict the behavior and prognosis of neoplasms. This is the first study to evaluate whether radiomic texture analysis can predict outcomes in gastroesophageal junction adenocarcinoma (GEJAC) treated with neoadjuvant chemoradiotherapy (CRT). Materials and Methods: Pretreatment contrast-enhanced CT images of 146 patients with stage II-III GEJAC were reviewed (2009-2011), and randomly split into training and validation groups at a 1:1 ratio stratified with baseline clinical characteristics. Whole-tumor texture was assessed using quantitative image features based on intensity, shape, and gray-level co-occurrence matrix. The relevant pretreatment texture features, in addition to the significant baseline clinical features to predict survival, were identified using multivariate Cox proportional hazard regression model with stepwise variable selection in the training sample and verified in the validation sample, to facilitate the proposal of a multi-point index for standard patient pre-treatment risk classification. Results: Of the factors identified in the training cohort independently associated with OS, only shape compactness (p = 0.04) and pathologic grade differentiation (PDG) (p = 0.02) were confirmed in the validation sample. Using both parameters, we created a 3-point risk classification index: low-risk (wellmoderate PDG and high compactness), medium-risk (poor PDG or low compactness), and high-risk (poor PDG and low compactness). The risk index showed a strong negative association with postoperative pathologic complete response (pCR) (p = 0.04). Median OS for the high-, medium-, and low-risk groups were 23, 51, and ≥ 72 months, respectively (p < 0.01). Similar results were seen with progression-free survival (respective 5-year rates of 15%, 30%, and 63%). Conclusion: Radiomic texture analysis can be used to stratify patients with GEJAC receiving trimodality therapy based on prognosis. The risk scoring system based on shape compactness and PDG shows a great potential for pre-treatment risk classification to guide surgical resection in locally advanced disease. Though in need of greater validation, these hypothesis-generating data could provide a unique platform of personalized oncologic care. © 2017 The Authors.

基金:
语种:
被引次数:
WOS:
JCR分区:
出版当年[2017]版:
最新[2023]版:
Q1 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Q2 ONCOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2016版] 出版当年五年平均 出版前一年[2016版]

第一作者:
第一作者机构: [a]Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Texas, USA [b]Department of Radiation Oncology, Sichuan Cancer Hospital, Chengdu, China
共同第一作者:
通讯作者:
通讯机构: [a]Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Texas, USA [*1]Department of Radiation Oncology, the University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Texas, TX 77030, USA
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:53699 今日访问量:0 总访问量:4607 更新日期:2025-02-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号